PDCD1 and neoplasm: Pretreatment with broad-spectrum antibiotics aggravates the gut dysbiosis that blunts programmed cell death protein 1 (PD-1) blockade in tumor-bearing mice, whereas SPIOCA administration reconstituted the gut microbiota and thereby resensitized tumors to anti-PD-1 therapy.